Drug profile

The FDA adverse-event record for Gentamicin Sulfate + Betamethasone + Clortrimazole

28 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Gentamicin Sulfate + Betamethasone + Clortrimazole. See the species affected, top reactions, and outcomes below.

28
adverse-event reports
0.0%
death-coded share
Dog
most-reported species
8
Emesis - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
28
Total Reports
0
Deaths Reported
0.0%
Death Rate

Active Ingredients

Gentamicin Sulfate + Betamethasone + Clortrimazole

Administration Routes

Auricular (Otic)UnknownTopical

Species Affected

Dog 26
Cat 2

Most Affected Breeds

Retriever - Golden 3
Retriever - Labrador 2
Beagle 2
Shih Tzu 2
Crossbred Canine/dog 1
Retriever (unspecified) 1
Terrier - Boston 1
Mastiff 1
Chihuahua 1
Poodle (unspecified) 1

Most Reported Reactions

Emesis 8
Vomiting 6
Lethargy (see also Central nervous system depression in 'Neurological') 5
Deafness 2
Ear discharge 2
Anorexia 2
Otorrhoea 2
Diarrhoea 2
Lack of efficacy - NOS 2
Weakness 2
Drooling 2
Pica NOS 1

Outcome Breakdown

Recovered/Normal
16 (57.1%)
Outcome Unknown
6 (21.4%)
Ongoing
5 (17.9%)
Recovered with Sequela
1 (3.6%)

Gentamicin Sulfate + Betamethasone + Clortrimazole Adverse Event Insights

28 reports name Gentamicin Sulfate + Betamethasone + Clortrimazole; 0 recorded a death outcome (0.0% of reported events, not a population-level mortality rate). Active ingredient: Gentamicin Sulfate + Betamethasone + Clortrimazole. Administration routes: Auricular (Otic), Unknown, Topical.

By species: Dog (26 reports), Cat (2 reports). By breed: Retriever - Golden (3), Retriever - Labrador (2), Beagle (2).

Leading clinical signs: Emesis (8), Vomiting (6), Lethargy (see also Central nervous system depression in 'Neurological') (5), Deafness (2). Outcome, 28 coded reports: Recovered/Normal leads at 57.1%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.